The Role of Prolactin in Mammary Carcinoma
Author(s) -
Charles V. Clevenger,
Priscilla A. Furth,
Susan E. Hankinson,
Linda A. Schuler
Publication year - 2003
Publication title -
endocrine reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.357
H-Index - 272
eISSN - 1945-7189
pISSN - 0163-769X
DOI - 10.1210/er.2001-0036
Subject(s) - autocrine signalling , prolactin , paracrine signalling , biology , prolactin receptor , cancer research , receptor , cytokine , signal transduction , endocrinology , medicine , microbiology and biotechnology , hormone , immunology , genetics
The contribution of prolactin (PRL) to the pathogenesis and progression of human breast cancer at the cellular, transgenic, and epidemiological levels is increasingly appreciated. Acting at the endocrine and autocrine/paracrine levels, PRL functions to stimulate the growth and motility of human breast cancer cells. The actions of this ligand are mediated by at least six recognized PRL receptor isoforms found on, or secreted by, human breast epithelium. The PRL/PRL receptor complex associates with and activates several signaling networks that are shared with other members of the cytokine receptor superfamily. Coupled with the recently identified intranuclear function of PRL, these networks are integrated into the in vitro and in vivo actions induced by ligand. These findings indicate that antagonists of PRL/PRL receptor interaction or PRL receptor-associated signal transduction may be of considerable utility in the treatment of human breast cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom